Literature DB >> 19828064

Knowledge synthesis of benefits and adverse effects of measles vaccination: the Lasbela balance sheet.

Robert J Ledogar1, John Fleming, Neil Andersson.   

Abstract

BACKGROUND: In preparation for a cluster-randomized controlled trial of a community intervention to increase the demand for measles vaccination in Lasbela district of Pakistan, a balance sheet summarized published evidence on benefits and possible adverse effects of measles vaccination.
METHODS: The balance sheet listed: 1) major health conditions associated with measles; 2) the risk among the unvaccinated who contract measles; 3) the risk among the vaccinated; 4) the risk difference between vaccinated and unvaccinated; and 5) the likely net gain from vaccination for each condition.
RESULTS: Two models revealed very different projections of net gain from measles vaccine. A Lasbela-specific combination of low period prevalence of measles among the unvaccinated, medium vaccination coverage and low vaccine efficacy rate, as revealed by the baseline survey, resulted in less-than-expected gains attributable to vaccination. Modelled on estimates where the vaccine had greater efficacy, the gains from vaccination would be more substantial.
CONCLUSION: Specific local conditions probably explain the low rates among the unvaccinated while the high vaccine failure rate is likely due to weaknesses in the vaccination delivery system. Community perception of these realities may have had some role in household decisions about whether to vaccinate, although the major discouraging factor was inadequate access. The balance sheet may be useful as a communication tool in other circumstances, applied to up-to-date local evidence.

Entities:  

Year:  2009        PMID: 19828064      PMCID: PMC3226238          DOI: 10.1186/1472-698X-9-S1-S6

Source DB:  PubMed          Journal:  BMC Int Health Hum Rights        ISSN: 1472-698X


  32 in total

1.  Immunogenicity and efficacy of one dose measles-mumps-rubella (MMR) vaccine at twelve months of age as compared to monovalent measles vaccination at nine months followed by MMR revaccination at fifteen months of age.

Authors:  M Ceyhan; G Kanra; G Erdem; B Kanra
Journal:  Vaccine       Date:  2001-08-14       Impact factor: 3.641

2.  Neurologic disorders after measles-mumps-rubella vaccination.

Authors:  Annamari Mäkelä; J Pekka Nuorti; Heikki Peltola
Journal:  Pediatrics       Date:  2002-11       Impact factor: 7.124

3.  Serological evaluation of a measles, mumps, and rubella vaccine.

Authors:  C M Robertson; V J Bennett; N Jefferson; R T Mayon-White
Journal:  Arch Dis Child       Date:  1988-06       Impact factor: 3.791

4.  Frequency of true adverse reactions to measles-mumps-rubella vaccine. A double-blind placebo-controlled trial in twins.

Authors:  H Peltola; O P Heinonen
Journal:  Lancet       Date:  1986-04-26       Impact factor: 79.321

5.  Clinical evaluation of a new measles-mumps-rubella trivalent vaccine.

Authors:  A J Schwarz; J E Jackson; N J Ehrenkranz; A Ventura; G M Schiff; V W Walters
Journal:  Am J Dis Child       Date:  1975-12

6.  Benefits, risks and costs of immunization for measles, mumps and rubella.

Authors:  C C White; J P Koplan; W A Orenstein
Journal:  Am J Public Health       Date:  1985-07       Impact factor: 9.308

7.  An evaluation of measles, mumps and rubella vaccine in a population of Yorkshire infants.

Authors:  J M Dunlop; K RaiChoudhury; J S Roberts; K A Bryett
Journal:  Public Health       Date:  1989-09       Impact factor: 2.427

8.  Epidemiological geomatics in evaluation of mine risk education in Afghanistan: introducing population weighted raster maps.

Authors:  Neil Andersson; Steven Mitchell
Journal:  Int J Health Geogr       Date:  2006-01-03       Impact factor: 3.918

9.  Separate spheres and indirect benefits.

Authors:  Dan W Brock
Journal:  Cost Eff Resour Alloc       Date:  2003-02-26

10.  Is cost-effectiveness analysis preferred to severity of disease as the main guiding principle in priority setting in resource poor settings? The case of Uganda.

Authors:  Lydia Kapiriri; Trude Arnesen; Ole Frithjof Norheim
Journal:  Cost Eff Resour Alloc       Date:  2004-01-08
View more
  7 in total

1.  The fallacy of coverage: uncovering disparities to improve immunization rates through evidence. Results from the Canadian International Immunization Initiative Phase 2 - Operational Research Grants.

Authors:  Sharmila L Mhatre; Anne-Marie Schryer-Roy
Journal:  BMC Int Health Hum Rights       Date:  2009-10-14

2.  Community perception regarding childhood vaccinations and its implications for effectiveness: a qualitative study in rural Burkina Faso.

Authors:  M Kagoné; M Yé; E Nébié; A Sié; O Müller; C Beiersmann
Journal:  BMC Public Health       Date:  2018-03-06       Impact factor: 3.295

3.  Global immunization: status, progress, challenges and future.

Authors:  Philippe Duclos; Jean-Marie Okwo-Bele; Marta Gacic-Dobo; Thomas Cherian
Journal:  BMC Int Health Hum Rights       Date:  2009-10-14

4.  Evidence-based discussion increases childhood vaccination uptake: a randomised cluster controlled trial of knowledge translation in Pakistan.

Authors:  Neil Andersson; Anne Cockcroft; Noor M Ansari; Khalid Omer; Manzoor Baloch; Ari Ho Foster; Bev Shea; George A Wells; José Legorreta Soberanis
Journal:  BMC Int Health Hum Rights       Date:  2009-10-14

5.  Measles epidemic in pakistan: in search of solutions.

Authors:  Ak Niazi; R Sadaf
Journal:  Ann Med Health Sci Res       Date:  2014-01

6.  Benefit-Risk Assessment of Vaccines. Part II: Proposal Towards Consolidated Standards of Reporting Quantitative Benefit-Risk Models Applied to Vaccines (BRIVAC).

Authors:  Hugo Arlegui; Kaatje Bollaerts; Vincent Bauchau; Gaëlle Nachbaur; Bernard Bégaud; Nicolas Praet
Journal:  Drug Saf       Date:  2020-11       Impact factor: 5.606

Review 7.  Benefit-Risk Assessment of Vaccines. Part I: A Systematic Review to Identify and Describe Studies About Quantitative Benefit-Risk Models Applied to Vaccines.

Authors:  Hugo Arlegui; Kaatje Bollaerts; Francesco Salvo; Vincent Bauchau; Gaëlle Nachbaur; Bernard Bégaud; Nicolas Praet
Journal:  Drug Saf       Date:  2020-11       Impact factor: 5.606

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.